CS Cancer Solutions
Institutional Oncology Intelligence Suite
Proposal for Hospitals, Cancer Centers & Research Institutions
1. Executive Summary
Oncology is evolving at unprecedented speed. Biomarkers, targeted therapies, and rapidly shifting clinical trial landscapes make it difficult for institutions to maintain synchronized, evidence-informed awareness across departments and sites.
CS Cancer Solutions provides a unified global oncology intelligence platform designed to support clinical decision-making, research operations, and institutional strategy.
Our Institutional and Enterprise packages deliver:
- Real-time global cancer intelligence
- Precision oncology insights
- Biomarker–therapy connections
- Worldwide clinical trial visibility
- Evidence summaries for tumor boards
- Institutional dashboards and custom analytics
- Unlimited access for clinicians and researchers
This proposal outlines the full capabilities available through custom enterprise deployments, typically ranging from mid–six figures to multi–million dollar annual engagements depending on scope.
Custom Enterprise Engagements
Custom enterprise deployments are scoped collaboratively based on institutional size, number of sites, and selected capability modules.
Typical annual investment range: $250,000 – $5,000,000+
2. About CS Cancer Solutions
CS Cancer Solutions aggregates and structures global oncology evidence from:
Evidence is synthesized and organized within a governed, tier-aware framework aligned with public oncology standards and peer-reviewed literature.
- NCI (US)
- ESMO (Europe)
- ASCO & AACR
- International cancer registries
- Precision oncology databases
- Clinical trial registries worldwide
- High-impact oncology journals
- Drug regulatory agencies (FDA, EMA, TGA, PMDA, etc.)
We transform this information into actionable, streamlined intelligence for:
- Hospitals
- Cancer centers
- Academic medical institutions
- Research groups
- Clinical trial offices
Our mission is to empower oncology teams with clear, evidence-based, globally sourced cancer intelligence.
Precision Oncology Enterprise Capabilities
(Available via Custom Enterprise Deployment)
Advanced Research & Institutional Intelligence Layer
Intended for: Hospitals, cancer centers, and academic medical institutions seeking advanced, institution-level precision oncology research intelligence to support translational research, tumor board preparation, institutional analytics, and long-term oncology strategy.
This tier builds on the Institutional Oncology Intelligence Suite (Tier 1) by adding deeper molecular context, advanced evidence mapping, and institutional customization.
Purpose & Scope
The Precision Oncology Enterprise Package provides advanced oncology research intelligence infrastructure designed to support:
- Molecular and biomarker-driven research programs
- Translational oncology initiatives
- Precision oncology education and planning
- Tumor board evidence preparation (educational reference only)
- Institutional analytics and strategy development
1. Precision Oncology Knowledge Graph (Institutional Access)
Institution-level access to a structured oncology knowledge graph providing educational and research context across:
- Biomarker → therapy research relationships
- Mechanisms of action (MoA) summaries
- Known resistance pathways (literature-based)
- Gene–variant interpretation frameworks (descriptive, not diagnostic)
- Public clinical trial mapping by molecular profile
- Evidence confidence and maturity indicators
All mappings are derived from peer-reviewed literature, regulatory sources, and public registries, with transparent sourcing.
2. Expanded Data Licensing & Institutional Use Rights
Institutions may use licensed data for internal educational and research purposes, including:
- Internal analytics and research modeling
- Institutional dashboards and reports
- Research tool development
- Grant preparation and academic publications
- Non-commercial AI/ML experimentation and validation
Important: Data licensing does not include commercial resale, clinical automation, or patient-level application.
3. Custom Institutional Intelligence Dashboard
A customized, institution-specific dashboard designed collaboratively to support:
- Clinical trial landscape analytics (descriptive)
- Research activity and enrollment trend visibility
- Oncology program and service-line overview
- Drug approval and pipeline awareness
- Tumor board evidence summaries (reference-only)
Dashboards are informational and strategic, not operational clinical systems.
4. Annual Oncology Grand Rounds (Educational)
One annual educational presentation delivered by CS Cancer Solutions leadership, focused on:
- Global oncology research trends
- Precision oncology developments
- Emerging biomarkers and therapeutic classes
- Trial landscape evolution
- International evidence context
Presentations are educational only and may be delivered virtually or onsite.
5. Dedicated Research Intelligence Analyst (Shared Allocation)
A dedicated analyst assigned to the institution to:
- Prepare custom research summaries
- Support tumor board evidence preparation (non-directive)
- Respond to research and strategy questions
- Assist with translational and precision oncology planning
Analyst support is research-focused, not clinical consultation.
6. Priority API Access
Early access to new:
- Oncology intelligence datasets
- Knowledge graph expansions
- Evidence classification updates
- Research indexing layers
This ensures institutions remain at the leading edge of global oncology intelligence.
7. Enterprise Support & Governance Coordination
- Priority support response
- Dedicated onboarding and implementation assistance
- Documentation support for compliance, IT, and governance review
- Ongoing platform optimization aligned with institutional needs
Governance & Compliance Alignment
- No PHI collected, stored, or processed
- No patient-level data
- No diagnostic or treatment recommendations
- No automated clinical decision support
- Designed for use outside EHR systems
- SOC2-aligned security practices
- Transparent sourcing and evidence standards
This tier is intentionally structured to reduce compliance risk while enabling advanced oncology intelligence use.
Who This Tier Is Best For
- Academic cancer centers with precision oncology programs
- Hospitals expanding molecular tumor boards
- Research institutions advancing translational oncology
- Systems developing internal oncology analytics
- Institutions preparing for future AI-enabled research (non-clinical)
Comprehensive Oncology Intelligence Network Capabilities
Enterprise-Scale Research & Operations Intelligence
Intended for: Large cancer centers, regional health systems, and multi-hospital networks seeking enterprise-wide oncology intelligence, cross-departmental research coordination, and system-level visibility into global oncology evidence, trials, and emerging standards.
This tier is designed for institutions that require multi-site scale, operational awareness, and advanced research intelligence, while remaining non-PHI, non-prescriptive, and governance-aligned.
Purpose & Scope
The Comprehensive Oncology Intelligence Network provides system-level oncology intelligence to support:
- Multi-hospital research coordination
- Enterprise oncology program planning
- Clinical trial operations visibility (non-PHI)
- Precision oncology research awareness
- Tumor board and leadership evidence preparation (reference only)
1. Oncology Command Center Dashboard (Enterprise Edition)
A centralized, enterprise-wide intelligence dashboard providing descriptive visibility into:
- Oncology research and activity trends across hospital sites
- Multi-center clinical trial activity and distribution
- Biomarker adoption patterns (aggregate, non-patient-specific)
- Therapy class utilization trends (descriptive, not directive)
- International guideline and standard-of-care variation
- System-level oncology performance indicators
Designed for leadership awareness, research coordination, and strategic planning.
2. Multi-Hospital Enterprise Licensing
Includes enterprise access for up to 6 hospital sites, with:
- Unlimited clinician users
- Unlimited researchers
- Unlimited trial coordinators
- Unlimited residents and fellows
Additional hospitals may be added depending on scope and customization.
3. Custom Oncology Intelligence Modules
Institution-specific intelligence modules developed collaboratively, such as:
- Breast cancer program intelligence hub
- Lung cancer research and trial dashboard
- GI oncology precision research tracker
- Hematologic malignancy trial landscape module
Modules are research- and education-focused, designed to support program oversight and evidence awareness.
4. Integrated Clinical Trial Intelligence Suite (Non-PHI)
Enterprise trial intelligence tools supporting:
- Global clinical trial tracking and indexing
- Study activation and status awareness
- Trial landscape mapping by disease area
- Enrollment trend analysis (aggregate)
- Competition scanning across institutions and regions
All functionality is descriptive and informational, with no patient-level data.
5. Precision Oncology Research Sequencing Insights
A non-PHI research intelligence module providing:
- Descriptive therapy sequencing frameworks (literature-based)
- Biomarker implications across therapy classes
- Global care pathway variations
- Resistance mechanism mapping (research context)
- Upstream and downstream research relationships
This module is intended for research planning and education, not treatment selection.
6. Semi-Annual Enterprise Oncology Strategy Summits
Two strategic meetings per year with institutional leadership, focused on:
- Oncology program review
- Global research and trial trends
- Precision oncology research direction
- Institutional alignment across departments
- Long-term oncology intelligence planning
Delivered virtually or onsite.
7. Dedicated Enterprise Intelligence Analyst (Part-Time Allocation)
A designated analyst supporting the institution with:
- Custom institutional reports
- Leadership briefing materials
- Trial office intelligence support
- Research and operations questions
- Tumor board evidence preparation (reference-only)
Analyst support is non-clinical and non-directive.
8. Enterprise API Priority & Custom Intelligence Endpoints
Priority access to enterprise APIs and custom endpoints, such as:
- Therapy class and sequencing intelligence APIs
- Global outcomes and survival data (aggregate, published sources)
- Biomarker prevalence by geography
- Trial sponsor and pipeline intelligence
- Drug mechanism and modality clustering
Endpoints are designed for research, analytics, and institutional intelligence use.
Governance & Compliance Alignment
- No PHI collected, stored, or processed
- No patient-level analytics
- No diagnostic or treatment automation
- Designed outside EHR systems
- Transparent sourcing and evidence standards
- SOC2-aligned security practices
This tier is structured to maximize institutional value while minimizing compliance burden.
Who This Tier Is Best For
- Regional health systems with multiple oncology sites
- Large cancer centers coordinating enterprise research
- Institutions managing complex trial portfolios
- Systems scaling precision oncology programs
- Organizations preparing for future AI-enabled research workflows (non-clinical)
Summary
The Comprehensive Oncology Intelligence Network delivers enterprise-scale oncology intelligence — enabling clarity, coordination, and strategic confidence across multi-hospital systems without replacing clinical judgment or care delivery infrastructure.
Global Precision Oncology Enterprise System Capabilities
Institutional-Scale Oncology Intelligence Infrastructure
Intended for:
NCI-designated cancer centers, multinational hospital networks, and academic research systems requiring global-scale oncology intelligence, advanced research infrastructure, and institution-wide coordination — without reliance on protected health information (PHI).
This tier is designed for organizations operating at the highest levels of oncology research, precision medicine programs, and enterprise strategy.
Strategic Positioning
The Global Precision Oncology Enterprise System provides a non-PHI, governance-safe oncology intelligence backbone that complements — but does not replace — clinical systems, genomic testing vendors, or treatment decision frameworks.
Distinctive advantage: Global evidence synthesis + modular deployment + institutional ownership.
1. Global Oncology Knowledge Graph (Institution-Level License)
An institution-licensed oncology knowledge graph mapping relationships across:
- Biomarkers and molecular alterations
- Drug mechanisms and therapy classes
- Descriptive therapy sequencing frameworks (research-based)
- Resistance patterns and pathway relationships
- Gene–variant interpretation (literature-sourced)
Integrated with:
- Global treatment standards and guideline variation
- Evidence confidence and maturity scoring
- Trial–molecule–mechanism relationships
- Cross-country oncology practice comparisons
Supports: Tumor board preparation (reference-only), precision oncology research programs, clinical pathway awareness (non-directive), grant development, and molecular tumor board discussion support.
2. Multi-National Enterprise Licensing
Enterprise licensing for up to 12 hospitals, including:
- Hospital networks
- Academic campuses
- Cancer research institutes
- Affiliated regional hospitals
Includes unlimited users across clinical, research, and educational roles.
Additional institutions may be added based on scope and customization requirements.
3. Custom Precision Oncology Pathway Intelligence Engine
A descriptive, research-focused pathway intelligence engine tailored to the institution, providing:
- Therapy sequencing frameworks based on published evidence
- Biomarker–therapy relationship mapping
- Global care pathway variation analysis
- Resistance mechanism context
- Literature-based therapy rationale summaries
4. Enterprise Research Intelligence Department (Hybrid Model)
Institution-supported research intelligence structure including:
- One full-time oncology research analyst (institution-provided)
- One part-time analyst (institution-provided)
- Monthly custom research intelligence reports
- Support for trial design and feasibility assessment
- Evidence synthesis for grant and publication development
- Annual institutional oncology intelligence review
Note: CS Cancer Solutions provides methodology, structure, and intelligence frameworks — not clinical direction.
5. Precision Oncology Collaboration Network Access
Institutional access to a global collaboration network including:
Purpose: Designed to support research collaboration, trial visibility, and academic exchange, not patient referral or recruitment.
6. Full Data Ownership & Private Cloud Deployment
Institutions may elect to:
- Host oncology intelligence datasets in private cloud or on-prem environments
- Integrate intelligence into proprietary analytics systems
- Conduct internal research analytics
- Support non-commercial AI/ML research initiatives
- Use synthesized intelligence in publications and grant materials
Data sourcing: All data is curated from public and licensed sources.
7. AI-Assisted Oncology Intelligence Tools (Non-PHI)
Custom AI-assisted tools designed to support research synthesis and evidence awareness, including:
- Automated trial landscape summaries
- Descriptive therapy sequencing maps
- Biomarker consideration frameworks
- Global guideline comparison summaries
- Identification of research gaps and opportunities
Governance, Compliance & Risk Alignment
- No PHI ingestion or processing
- No patient-level analytics
- No diagnostic or treatment automation
- Designed outside EHR and clinical decision systems
- Transparent sourcing and evidence governance
- SOC2-aligned infrastructure and documentation
This tier is intentionally designed to streamline procurement, IT approval, and institutional risk review.
Who This Tier Is Best For
- NCI-designated cancer centers
- Multinational academic hospital systems
- Institutions leading precision oncology research
- Organizations building enterprise oncology intelligence infrastructure
- Centers preparing for future AI-enabled research environments without clinical risk
Summary
The Global Precision Oncology Enterprise System positions CS Cancer Solutions as an institutional oncology intelligence partner — delivering global evidence integration, research-grade analytics, and scalable infrastructure while preserving clinical independence, governance integrity, and institutional trust.
Systemwide Precision Oncology Transformation Suite Capabilities
Enterprise-Scale Oncology Intelligence & Research Infrastructure
Intended for:
Large hospital systems, regional cancer networks, and academic medical centers seeking to standardize oncology intelligence, strengthen research operations, and align precision oncology strategy across multiple sites — without reliance on protected health information (PHI).
This tier is designed for organizations ready to move from departmental precision oncology initiatives to a systemwide intelligence framework.
Strategic Purpose
The Systemwide Precision Oncology Transformation Suite delivers an enterprise-wide oncology intelligence platform that supports:
- Research-informed oncology strategy
- Systemwide evidence consistency
- Trial operations visibility
- Precision oncology program alignment
- Education, planning, and translational research
1. Enterprise-Wide Oncology Intelligence Platform (All Hospitals Included)
Full access for:
- All hospital sites (unlimited)
- Outpatient cancer centers
- Research departments
- Oncology service lines
- Trial offices
- Residents & fellows
Includes:
- Global oncology intelligence
- Real-time evidence updates
- Comprehensive therapy + biomarker insights
- Clinical trial landscape tracking
2. Precision Oncology Department Build-Out (Staff Provided by CS Cancer Solutions)
Your system receives:
- 1 Full-Time Senior Research Intelligence Analyst
- 1 Full-Time Precision Oncology Evidence Specialist
- 1 Part-Time Clinical Trial Intelligence Associate
Provides:
- Tumor board evidence briefs
- Research reports
- Trial matching support (non-PHI)
- Evidence synthesis for grants
- Department-level analytics
3. Custom Precision Oncology Pathway Intelligence Engine
A system-specific, descriptive pathway intelligence engine providing:
- Literature-based therapy sequencing frameworks
- Biomarker-driven evidence context
- Resistance mechanism summaries
- Global treatment guideline variation analysis
- Evidence grading and maturity indicators
This engine is designed to inform discussion, education, and research planning. It complements NCCN guidelines and institutional protocols.
4. Systemwide Clinical Trial Operations Intelligence Suite
An enterprise research operations layer supporting:
- Global trial availability mapping
- Study activation and feasibility awareness
- Competitive trial landscape scanning
- Investigator and sponsor visibility dashboards
- Disease-area enrollment trend analysis
5. Oncology Program Intelligence Dashboards
Custom analytics dashboards for:
Includes:
- Therapy trends
- Biomarker adoption
- Clinical pathway variations
- Department performance indicators
6. Annual Systemwide Precision Oncology Strategy Summit
One onsite, full-day strategic summit including:
- Chief Medical Officer
- Oncology program leadership
- Research and trial leadership
- Clinical education leaders
- Philanthropy and strategy stakeholders
Deliverables include:
- Systemwide oncology intelligence review
- Precision oncology strategy alignment
- Research and trial opportunity mapping
- Evidence-informed roadmap documentation
7. 24/7 Priority Support & Dedicated Account Management
- Dedicated institutional account leadership
- Priority response (<2-hour SLA for enterprise issues)
- White-glove onboarding and ongoing support
- Proactive roadmap and capability planning
Governance, Compliance & Risk Alignment
- No PHI ingestion or processing
- No diagnostic, predictive, or prescriptive functionality
- No EHR integration required
- Transparent sourcing and evidence governance
- SOC2-aligned infrastructure and documentation
This tier is intentionally designed to reduce procurement friction while enabling deep institutional impact.
Who This Tier Is Best For
- Regional and multi-site hospital systems
- Academic medical centers with complex oncology programs
- Institutions scaling precision oncology across service lines
- Health systems strengthening trial operations and research coordination
- Organizations preparing for future AI-enabled research environments without clinical risk
Summary
The Systemwide Precision Oncology Transformation Suite enables institutions to standardize oncology intelligence, elevate research operations, and align precision oncology strategy at scale — while preserving clinical independence, governance integrity, and institutional trust.
Global Oncology Intelligence Infrastructure Partnership
(Flagship Custom Program)
For billion-dollar health systems, NCI-designated cancer centers, and multinational research networks
This tier positions CS Cancer Solutions as a long-term oncology intelligence infrastructure partner, not a software vendor. It provides private, institution-controlled oncology intelligence systems, global evidence infrastructure, and research-grade analytics — without the use of protected health information (PHI).
This partnership is designed to support research, education, strategy, and institutional oncology intelligence, not clinical care delivery.
🔶 1. Private Cloud Residency & Secure Intelligence Infrastructure
A custom-built, institution-exclusive environment including:
- Encrypted private cloud or on-prem deployment
- Institution-specific authentication and access controls
- Continuous uptime monitoring and redundancy
- Dedicated DevOps and infrastructure support
This infrastructure ensures full institutional control, isolation, and governance at enterprise scale.
🔶 2. Multi-National Institutional Licensing (Up to 20 Hospitals)
Enterprise-wide access across:
- Domestic hospital systems
- International affiliates
- Academic research programs
- Satellite clinics and oncology networks
Includes unlimited users across all licensed entities. Additional institutions may be licensed by agreement.
🔶 3. Global Oncology Knowledge Graph — Institutional License
The foundational intelligence asset of this flagship partnership.
Provides structured, evidence-tiered mappings of:
- Biomarkers, variants, and molecular contexts
- Drug mechanisms and therapy classes
- Evidence-linked therapy sequencing context (descriptive, non-prescriptive)
- Resistance mechanism summaries
- Trial–molecule–evidence relationships
- Cross-country guideline comparisons
- Evidence confidence and maturity scoring
Designed to support tumor board preparation, precision oncology research, translational planning, grant development, and institutional strategy.
🔶 4. AI-Assisted Oncology Intelligence Modules (Non-PHI)
Governed, non-diagnostic intelligence augmentation tools, including:
- Automated evidence summaries for tumor board reference
- Clinical trial landscape synthesis and comparison
- Therapy sequence context mapping
- Biomarker and resistance mechanism alerts
- Global guideline variation analysis
🔶 5. Enterprise Oncology Research Intelligence Team (CS-Provided)
CS Cancer Solutions provides an embedded intelligence team, typically including:
- 1 Senior Oncology Intelligence Director
- 2 Full-Time Oncology Research Analysts
- 1 Precision Oncology Pathways Coordinator
- 1 Clinical Trial Intelligence Specialist
This team supports:
- Tumor board reference materials
- Research development and grant support
- Trial intelligence and feasibility analysis
- Institutional oncology reporting and strategy
- Evidence synthesis for academic and operational use
All outputs are educational, research-focused, and non-prescriptive.
🔶 6. Co-Branded Oncology Innovation Partnership (Optional)
Creation of a joint institutional initiative, such as:
"CS Cancer Solutions × [Institution Name] Global Oncology Intelligence Center"
Used for:
- Research collaboration visibility
- Academic and philanthropic engagement
- Institutional thought leadership
- Oncology innovation recognition
Participation and branding are governed collaboratively.
🔶 7. Executive Quarterly Strategy Summits (Onsite)
Four onsite strategy sessions per year with:
- Chief Medical Officer
- Chief Information Officer
- Oncology Chairs and Program Directors
- Research and Trial Leadership
- Institutional Strategy and Philanthropy Leaders
Each summit delivers:
- Oncology intelligence review
- Research and trial landscape analysis
- Precision oncology opportunity mapping
- Evidence-aligned institutional roadmap
🔶 8. Custom API Ecosystem & Data Residency Options
Includes:
- Full enterprise API access
- Custom endpoints developed on request
- Private model hosting environments
- Regional data residency options (U.S., EU, etc.)
- Secure AI model sandboxing for research use
Designed to support institution-controlled analytics and innovation.
A long-term oncology intelligence infrastructure partnership for institutions operating at global scale.
7. Compliance, Security & Data Governance
CS Cancer Solutions:
- Does not require PHI
- Provides non-identifiable aggregated data
- Follows SOC2-aligned practices
- Uses secure cloud infrastructure (AWS/Google Cloud)
- Offers institutional documentation upon request
No PHI = dramatically easier procurement & IT approval.
8. Implementation & Onboarding Timeline
CS Cancer Solutions follows a structured, institution-friendly onboarding process designed to minimize disruption and accelerate value realization.
Week 1
- • Kickoff meeting
- • User provisioning and access configuration
- • API access setup (if applicable)
Weeks 2–4
- • Platform orientation and training for clinicians, researchers, and administrators
- • Initial dashboard configuration and evidence access setup
Month 2
Customized institutional briefings and research intelligence delivery begin
Ongoing
- • Quarterly strategy and review sessions
- • Dashboard updates and intelligence refreshes
- • Continuous platform updates and new evidence integration
- • Enterprise support and account management
Timelines may be adjusted collaboratively to align with institutional workflows and governance requirements.
9. Institutional Value & Return on Investment Context
CS Cancer Solutions is positioned as an institutional intelligence accelerator — reducing fragmentation across research, trial operations, education, and strategy functions.
Institutions use CS Cancer Solutions to support:
- Improved visibility into global clinical trial landscapes
- Stronger evidence preparation for tumor boards and research discussions
- Reduced time spent synthesizing fragmented oncology research
- Better coordination across clinical, research, and trial operations
- Enhanced institutional readiness for precision oncology initiatives
The platform is designed to support operational efficiency, research effectiveness, and strategic planning.
Any financial or clinical outcomes depend on institutional implementation, governance, and use within appropriate professional frameworks.
10. Next Steps
To proceed:
- Review package options
- Schedule a demonstration
- Sign institutional agreement
- Begin onboarding
📩 Contact Sales: